NO20015756L - Common promotional drugs of amlodipine and atorvastatin - Google Patents
Common promotional drugs of amlodipine and atorvastatinInfo
- Publication number
- NO20015756L NO20015756L NO20015756A NO20015756A NO20015756L NO 20015756 L NO20015756 L NO 20015756L NO 20015756 A NO20015756 A NO 20015756A NO 20015756 A NO20015756 A NO 20015756A NO 20015756 L NO20015756 L NO 20015756L
- Authority
- NO
- Norway
- Prior art keywords
- amlodipine
- atorvastatin
- drugs
- compositions
- mammal
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000528 amlodipine Drugs 0.000 title abstract 2
- 229960005370 atorvastatin Drugs 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Det beskrives felles promedikamenter av amlodipin og atorvastatin og farmasøytiske blandinger derav. Det beskrives også fremgangsmåter for behandling av angina pectoris, aterosklerose og hypertensjon og hyperlipidemi i et pattedyr ved bruk av disse promedikamenter og blandinger. Det beskrives også fremgangsmåter for håndtering av hjertesykdomsrisiko i et pattedyr, inklusivt mennesker, som opp- viser symptomer på hjertesykdomsrisiko, ved å administrere slike promedikamenter og blandinger.Common prodrugs of amlodipine and atorvastatin and pharmaceutical compositions thereof are disclosed. Methods are also described for the treatment of angina pectoris, atherosclerosis and hypertension and hyperlipidemia in a mammal using these promedics and compositions. Methods for managing heart disease risk in a mammal, including humans, exhibiting symptoms of heart disease risk are also described by administering such promedicines and compositions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13660899P | 1999-05-27 | 1999-05-27 | |
| PCT/IB2000/000313 WO2000073298A1 (en) | 1999-05-27 | 2000-03-20 | Mutual prodrugs of amlodipine and atorvastatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20015756D0 NO20015756D0 (en) | 2001-11-26 |
| NO20015756L true NO20015756L (en) | 2002-01-24 |
Family
ID=22473579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015756A NO20015756L (en) | 1999-05-27 | 2001-11-26 | Common promotional drugs of amlodipine and atorvastatin |
Country Status (41)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800127A (en) * | 1997-08-29 | 2000-02-01 | THERAPEUTIC COMBINATIONS. | |
| US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| KR20070108282A (en) | 2001-06-11 | 2007-11-08 | 제노포트 인코포레이티드 | Dosage Forms for Oral Administration of BAAA Analog Prodrugs with Reduced Toxicity |
| DE10140421A1 (en) * | 2001-08-17 | 2003-03-06 | Bayer Ag | New combination |
| US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| AU2005301970B2 (en) | 2004-11-04 | 2011-06-02 | Arbor Pharmaceuticals, Llc | Gabapentin prodrug sustained release oral dosage forms |
| WO2007016306A2 (en) * | 2005-08-01 | 2007-02-08 | Psivida Inc. | HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF |
| AR057882A1 (en) | 2005-11-09 | 2007-12-26 | Novartis Ag | DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS |
| US8354116B2 (en) * | 2007-06-18 | 2013-01-15 | Biochemics, Inc. | Bifunctional synthetic molecules |
| US8371336B2 (en) | 2007-10-10 | 2013-02-12 | Eagle Industry Co., Ltd. | Accumulator |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK161312C (en) | 1982-03-11 | 1991-12-09 | Pfizer | CHANGES FOR THE PREPARATION FOR THE PREPARATION OF 2-Amino-CO-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-2-D-Hydroxy |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
| US5155120A (en) | 1991-01-14 | 1992-10-13 | Pfizer Inc | Method for treating congestive heart failure |
| GT199800127A (en) * | 1997-08-29 | 2000-02-01 | THERAPEUTIC COMBINATIONS. |
-
2000
- 2000-03-20 ES ES00911145T patent/ES2220426T3/en not_active Expired - Lifetime
- 2000-03-20 JP JP2000621364A patent/JP2003500487A/en active Pending
- 2000-03-20 EE EEP200100631A patent/EE200100631A/en unknown
- 2000-03-20 CN CN00808081A patent/CN1352640A/en active Pending
- 2000-03-20 KR KR1020017015185A patent/KR20020012247A/en not_active Ceased
- 2000-03-20 PL PL00353483A patent/PL353483A1/en not_active Application Discontinuation
- 2000-03-20 EP EP00911145A patent/EP1180102B9/en not_active Expired - Lifetime
- 2000-03-20 CZ CZ20014229A patent/CZ20014229A3/en unknown
- 2000-03-20 HR HR20010856A patent/HRP20010856A2/en not_active Application Discontinuation
- 2000-03-20 MX MXPA01012125A patent/MXPA01012125A/en active IP Right Grant
- 2000-03-20 SK SK1679-2001A patent/SK16792001A3/en unknown
- 2000-03-20 AT AT00911145T patent/ATE268764T1/en not_active IP Right Cessation
- 2000-03-20 DE DE60011424T patent/DE60011424T2/en not_active Expired - Fee Related
- 2000-03-20 AP APAP/P/2001/002345A patent/AP2001002345A0/en unknown
- 2000-03-20 EA EA200101130A patent/EA200101130A1/en unknown
- 2000-03-20 BR BR0011006-0A patent/BR0011006A/en not_active IP Right Cessation
- 2000-03-20 HU HU0201433A patent/HUP0201433A2/en unknown
- 2000-03-20 HK HK02107872.6A patent/HK1046282A1/en unknown
- 2000-03-20 PT PT00911145T patent/PT1180102E/en unknown
- 2000-03-20 CA CA002375372A patent/CA2375372C/en not_active Expired - Fee Related
- 2000-03-20 OA OA1200100312A patent/OA11950A/en unknown
- 2000-03-20 WO PCT/IB2000/000313 patent/WO2000073298A1/en not_active Ceased
- 2000-03-20 DK DK00911145T patent/DK1180102T3/en active
- 2000-03-20 TR TR2001/03391T patent/TR200103391T2/en unknown
- 2000-03-20 IL IL14594700A patent/IL145947A0/en unknown
- 2000-03-20 AU AU33139/00A patent/AU3313900A/en not_active Abandoned
- 2000-05-17 HN HN2000000075A patent/HN2000000075A/en unknown
- 2000-05-19 PA PA20008495701A patent/PA8495701A1/en unknown
- 2000-05-24 CO CO00038315A patent/CO5170457A1/en not_active Application Discontinuation
- 2000-05-24 US US09/577,561 patent/US6486182B1/en not_active Expired - Fee Related
- 2000-05-24 MA MA25986A patent/MA26736A1/en unknown
- 2000-05-24 TN TNTNSN00113A patent/TNSN00113A1/en unknown
- 2000-05-24 DZ DZ000092A patent/DZ3048A1/en active
- 2000-05-25 GT GT200000078A patent/GT200000078A/en unknown
- 2000-05-25 SV SV2000000082A patent/SV2002000082A/en not_active Application Discontinuation
- 2000-05-25 PE PE2000000498A patent/PE20010169A1/en not_active Application Discontinuation
- 2000-05-26 AR ARP000102581A patent/AR022344A1/en not_active Application Discontinuation
-
2001
- 2001-10-30 IS IS6135A patent/IS6135A/en unknown
- 2001-11-26 NO NO20015756A patent/NO20015756L/en not_active Application Discontinuation
- 2001-11-26 BG BG106149A patent/BG106149A/en unknown
- 2001-11-26 ZA ZA200109691A patent/ZA200109691B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20015756L (en) | Common promotional drugs of amlodipine and atorvastatin | |
| BG106128A (en) | Mutual salt of amlodipine and atorvastatin | |
| TR200000561T2 (en) | Therapeutic compounds containing amlodipine and atorvastatin. | |
| PT951474E (en) | NEW DERIVATIVES OF CICLOSPORIN ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| TR200000562T2 (en) | Composition therapy containing amlodipine and a statin compound | |
| DK0963200T3 (en) | Preparations for inhibiting angiogenesis comprising thalidomide and an NSAID | |
| HUS1200031I1 (en) | Cyclopropyl-fused pyrrolidine-based inhibitors and method for the preparation of dipeptidyl peptidase IV and pharmaceutical compositions containing them | |
| UY27402A1 (en) | PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN | |
| AU7001001A (en) | Modified forms of pharmacologically active agents and uses therefor | |
| DK1210119T3 (en) | Pharmaceutical compositions for oral and topical administration | |
| DK1071463T3 (en) | Process and compositions using terfenadine metabolites in combination with leukotriene inhibitors | |
| ATE350064T1 (en) | PHARMACEUTICAL COMPOSITIONS OF RAPAMYCINES | |
| ECSP003497A (en) | MUTUAL SALT OF AMLODIPINO AND ATORVASTATINA | |
| UY26164A1 (en) | MUTUAL PROPHARMACS OF AMLODIPINE AND ATORVASTATIN | |
| CA2361288A1 (en) | Mutual prodrug of amlodipine and atorvastatin | |
| UY27187A1 (en) | PHARMACEUTICAL COMPOSITIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |